PureTech Provides End of Year Report on Key Progress
CANNANNEW REPORT

Rapid advancement of PureTech’s Wholly Owned Pipeline, with three clinical trials now underway and five completed this year that demonstrated compelling safety and tolerability data for LYT-100 (deupirfenidone) and proof of principle, oral bioavailability and tolerability for LYT-300 (oral allopregnanolone). Robust dose escalation and safety data also announced from completed monotherapy portion of Phase 1 […]

Excerpt only …
READ MORE BELOW
Source : PureTech Provides End of Year Report on Key Progress

reposted by Cannabis News World